Home
  >  
Section 47
  >  
Chapter 46,968

Pharmacologic treatment of the critically ill patient with diabetes

Quinn, L.

Critical Care Nursing Clinics of North America 14(1): 81-98

2002

ISSN/ISBN: 0899-5885
PMID: 11939649
DOI: 10.1016/s0899-5885(03)00040-6
Accession: 046967782
Download citation:  
Text
  |  
BibTeX
  |  
RIS
The pharmacologic approach to the management of DKA and HHNS involves the use of insulin, fluids, and electrolytes. Essential to the successful treatment of DKA and HHNS is a carefully planned post-intensive-care transition period. This period is based on the understanding that insulin therapy is never interrupted in patients with type 1 diabetes and the transition to insulin and/or oral hypoglycemic therapy in type 2 patients is strategically planned. The use of acute adjuvant insulin-glucose therapy in acute coronary syndromes and cardiac surgeries can result in decrease in overall morbidity and mortality in patients with diabetes. Ultimately, however, the major approaches to the treatment of diabetes is primary prevention of diabetes itself and the secondary prevention of complications through vigorous glucose control.

PDF emailed within 0-6 h: $19.90




Related References

Siefkin, A.D. 1996: Optimal pharmacologic treatment of the critically ill patient with obstructive airways disease Am. J. Med 100(1A): 1A.54S-1A.61S
Siefkin, A.D. 1996: Optimal pharmacologic treatment of the critically ill patient with obstructive airways disease American Journal of Medicine 100(1a): 54S-61S
Devlin, J.W.; Al-Qadhee, N.S.; Skrobik, Y. 2012: Pharmacologic prevention and treatment of delirium in critically ill and non-critically ill hospitalised patients: a review of data from prospective, randomised studies Best Practice and Research. Clinical Anaesthesiology 26(3): 289-309
Smith, N.D. 2013: Orthostatic Hypotension in the Patient with Diabetes: A Broad Review of Pharmacologic Treatment Options The Journal of Pharmacy Technology 29(1): 23-34
Alverson, E.M. 1989: The Pharmacologic Approach to the Critically Ill Patient AORN Journal 49(2): 660-662
Majerus, T C. 1985: The pharmacologic approach to the critically ill patient American Journal of Emergency Medicine 3(2): 175-176
Patanwala, A.E.; Abarca, J.; Huckleberry, Y.; Erstad, B.L. 2006: Pharmacologic management of constipation in the critically ill patient PharmacoTherapy 26(7): 896-902
Chernow, B.; Zaloga, G.P. 1987: Pharmacologic management of the critically ill patient in the perioperative period--emphasis on the sepsis syndrome Medical Clinics of North America 71(3): 541-549
Chernow, B.; Zaloga, G.P. 1987: Pharmacologic management of the critically III patient in the perioperative period: emphasis on the sepsis syndrome The Medical Clinics of North America 71(3): 541-549
Flannery, J.; Tucker, D.A. 2002: Pharmacologic prophylaxis and treatment of stress ulcers in critically ill patients Critical Care Nursing Clinics of North America 14(1): 39-51
Gomez-Peralta, F.; Escalada San Martín, F.Javier.; Menéndez Torre, E.; Mata Cases, M.; Ferrer García, J.Carlos.; Ezkurra Loiola, P.; Ávila Lachica, L.; Fornos Pérez, J.Antonio.; Artola Menéndez, S.; Álvarez-Guisasola, F.; Rica Echevarría, I.; Girbés Borrás, J. 2018: Spanish Diabetes Society (SED) recommendations for the pharmacologic treatment of hyperglycemia in type 2 diabetes: 2018 Update Endocrinologia Diabetes y Nutricion 65(10): 611-624
Quinn, L. 2001: Pharmacologic management of the patient with type 2 diabetes Nursing Clinics of North America 36(2): 217-242 Vi
Neumiller, J.J.; Setter, S.M. 2009: Pharmacologic management of the older patient with type 2 diabetes mellitus American Journal of Geriatric PharmacoTherapy 7(6): 324-342
van Vught, L.A.; Scicluna, B.P.; Hoogendijk, A.J.; Wiewel, M.A.; Klein Klouwenberg, P.M.C.; Cremer, O.L.; Horn, J.; Nürnberg, P.; Bonten, M.M.J.; Schultz, M.J.; van der Poll, T. 2016: Association of diabetes and diabetes treatment with the host response in critically ill sepsis patients Critical Care 20(1): 252
Arabi, Y.M.; Alsolamy, S.; Al-Dawood, A.; Al-Omari, A.; Al-Hameed, F.; Burns, K.E.A.; Almaani, M.; Lababidi, H.; Al Bshabshe, A.; Mehta, S.; Al-Aithan, A.M.; Mandourah, Y.; Almekhlafi, G.; Finfer, S.; Abdukahil, S.A.I.; Afesh, L.Y.; Dbsawy, M.; Sadat, M. 2016: Thromboprophylaxis using combined intermittent pneumatic compression and pharmacologic prophylaxis versus pharmacologic prophylaxis alone in critically ill patients: study protocol for a randomized controlled trial Trials 17(1): 390
Sanderson, T.; Morris, M.; Calnan, M.; Richards, P.; Hewlett, S. 2010: Patient perspective of measuring treatment efficacy: the rheumatoid arthritis patient priorities for pharmacologic interventions outcomes Arthritis Care and Research 62(5): 647-656
Scheen, A.é J. 2015: Towards a genotype-based approach for a patient-centered pharmacologic therapy of type 2 diabetes Annals of Translational Medicine 3(Suppl 1): S36
De Montigny, P.; Clerc, C.; Descarpentries, C. 2006: Pharmacologic treatment of diabetes Perspective Infirmiere: Revue Officielle de l'Ordre des Infirmieres et Infirmiers du Quebec 4(2): 30-34
García de Lorenzo y Mateos, A.; Ortiz Leyba, C.; Sánchez, S.M. 2011: Guidelines for specialized nutritional and metabolic support in the critically-ill patient: update. Consensus SEMICYUC-SENPE: critically-ill burnt patient Nutricion Hospitalaria 26 Suppl. 2: 59-62
Alvarenga, M.A.; Komatsu, W.R.; de Sa, J.R.; Chacra, A.R.; Dib, S.A. 2018: Clinical inertia on insulin treatment intensification in type 2 diabetes mellitus patients of a tertiary public diabetes center with limited pharmacologic armamentarium from an upper-middle income country Diabetology and Metabolic Syndrome 10: 77